Dogma Biotech

Executive Summary

Dogma Biotech, a Colombian biotechnology firm founded in 2020, is pioneering RNA-targeted and gene-editing therapies to address unmet needs in oncology and rare diseases. Leveraging its proprietary platform, the company aims to develop disease-modifying treatments for solid tumors and genetically defined rare disorders. Currently in the preclinical stage, Dogma has raised $12 million to advance its pipeline, which targets indications with high genetic specificity. The company's approach combines rational design with delivery optimization, positioning it to potentially overcome key challenges in gene therapy. While still early-stage, Dogma's platform could yield first-in-class candidates if preclinical studies demonstrate favorable safety and efficacy profiles. Dogma Biotech operates in a competitive but rapidly evolving landscape, where RNA-targeted modalities have gained significant traction. The company's focus on rare genetic disorders offers a clear regulatory pathway and potential for accelerated approval, while its oncology programs address large markets. Key risks include preclinical validation, manufacturing scalability, and funding for clinical translation. With a lean team of 10-50 employees, Dogma appears well-positioned to achieve near-term milestones, such as in vivo proof-of-concept data and potential partnership discussions. The company's strategic location in Bogotá may provide cost advantages but also raises logistical considerations for global development. Overall, Dogma represents a high-risk, high-reward opportunity contingent on successful preclinical readouts and capital efficiency.

Upcoming Catalysts (preview)

• Q1 2027Release of in vivo efficacy data for lead oncology program65% success
• H2 2026Series B financing or strategic partnership70% success
• Q4 2026IND-enabling studies initiation for rare disease candidate55% success